Connection

Ki Chung to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Ki Chung has written about Antineoplastic Agents.
Ki Chung
Connection Strength
0.111
Antineoplastic Agents
  1. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 10 01; 27(19):5236-5247.
    View in: PubMed
    Score: 0.111
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.